Groups: CMS Has Tools To Fix IRA Formulary Issues That Limit Part D Savings To Patients

By Sigi Ris / July 12, 2024 at 1:46 PM
CMS has tools at its disposal to protect Part D beneficiaries from insurance policies the drug industry lobby says could limit patients’ ability to benefit from lower prices negotiated under the Inflation Reduction Act (IRA), according to a report from the Alliance of Aging Research and Manatt. The Alliance and Manatt suggest CMS set general minimum standards for plans participating in Part D, including regulating which drugs are put on plans’ specialty tiers, and improve the beneficiary appeals process. A...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.